Updated just now · Live
Stock analysis, price data, and AI-powered insights for Immuneering Corp (IMRX).
Immuneering Corp operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for IMRX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). IMRX Stock Intelligence Report. [stoxpulse.com/stocks/imrx]
Disclaimer: The information on this page about Immuneering Corp (IMRX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Immuneering Corp.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Immuneering Presents New Genetic Data At 2026 AACR...
1d ago
Immuneering Presents Genetic Data at AACR Annual M...
1d ago
StoxPulse AI results for IMRX: Pulse Score 52/100. Primary sentiment trends from 2 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$357.5M
P/E Ratio
—
EPS
$-0.38
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Immuneering Presents New Genetic Data At 2026 AACR Annual Meeting; Analysis Of Circulating Tumor DNA From Atebimetinib-Treated Patients Shows Acquired MAPK Pathway Alterations Are Rare, Supporting Observed Durable First-Line Activity
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond